PaxMedica (NASDAQ: PXMD) has jumped 92.7% on Friday following the company's announcement of significant advancements in its drug development program, which has been well-received by the market.
PaxMedica stock is surging on Friday following the achievement of a significant milestone in drug development, with the company successfully obtaining three crucial batches of PAX-101.
PaxMedica (NASDAQ: PXMD ) stock is cratering today after the company announced a $7 million public offering. The offering consists of 5.38 million shares and warrants to purchase up to 5.38 million shares.
PaxMedica (NASDAQ: PXMD ) stock is jumping significantly higher against the backdrop of another soft session on Wall Street. This morning, management announced a productive discussion with the U.S. Food and Drug Administration (FDA) over positive clinical trial results for a key drug.
Clinical-stage biopharmaceutical firm PaxMedica (NASDAQ: PXMD ) is experiencing a full range of emotions following an initial spike in the market today. Earlier this morning, the company announced encouraging top-line results from its Phase 3 trial of PAX-101 (intravenous suramin), which met its primary endpoint.